Global Stem Cell Manufacturing Market projected to be worth USD 24.77 billion by 2030.
According to SPER Market Research, the Stem Cell Manufacturing Market estimated to reach USD 24.77 billion by 2030 with a CAGR of 8.9%. Encouraging regulatory framework, increasing investments in stem cell-based research, and growing alertness regarding the therapeutic potency of stem cell products; are the fuels for the escalation of the market.
Impact of COVID-19 on the Stem Cell Manufacturing Market
The outbreak of COVID-19; lead to lockdown globally, in turn negatively impacted the stem cell manufacturing market.
Scope of the Report:
Market size available for years 2019-2030
Base year considered 2021
Forecast period 2022-2030
Segments covered By Product, By Application, By End-User, By Region
Geographies covered North America, Europe, Asia Pacific, Latin America , Middle East, Africa
Companies Covered Anterogen, Becton, Bio-Rad Laboratories, Bio-Techne Corporation, Cellgenix GMBH, Corning Inc., Danaher Corporation, Dickinson and Company, Eppendorf AG, Fujifilm Holdings Corporation, Getinge, Himedia Laboratories, Lonza Group AG, Merck Millipore, Miltenyi Biotec, Promocell, Sartorius AG, Stemcell Technologies, Takara Bio Group, Terumo BCT Inc., Thermo Fisher Scientific.
Driver: Increasing Venture Capital Investments in Stem Cell Research
The increase in the public-private partnership investment in research for developing stem cell based technology. Stem cells are effective in disease management, personalized medicine and genomic testing.
Restraint: Operational Costs Allied with Stem Cell Manufacturing and Banking
Expert techniques are used for stem cell isolation, purification, and storage. High operational cost coupled with stem cell manufacturing. Therefore, stem cell products are frequently available at a higher price than pharmaceutical drugs and biologics.
Opportunity: Encouraging Regulatory Framework Across Developing Countries
Regulatory reforms in the stem cell industries by the emerging countries meant for commercialization and research allied to stem cell therapy. Encouraging regulatory frameworks across developing countries are anticipated to offer huge opportunities to players in the market.
Challenges:
Technical limitations coupled with manufacturing scale-up, Socio-ethical concerns associated to the use of allogeneic and human embryonic stem cells; are the challenges to the market.
Global Stem Cell Manufacturing Market, By Product:
Based on the Product, Global Stem Cell Manufacturing Market is segmented as; Consumables (Culture Media, Other Consumables), Instruments (Bioreactors and Incubators, Cell Sorters, Other Instruments), Stem Cell Lines [Embryonic stem cells (ESC), Hematopoietic stem cells (HSC), Induced Pluripotent Stem cells (iPSC), Mesenchymal stem cells (MSC), Multipotent adult progenitor stem cells, Neural Stem cells (NSC)].
Global Stem Cell Manufacturing Market, By Application:
Based on the Application, Global Stem Cell Manufacturing Market is segmented as; Research Applications (Life science research, Drug discovery and development), Clinical Application (Allogenic stem cell therapy, Autologous stem cell therapy), Cell & Tissue Banking Applications.
Global Stem Cell Manufacturing Market, By End-User:
Based on the End-User, Global Stem Cell Manufacturing Market is segmented as; Pharmaceutical & Biotechnology Companies, Academic institutes, Research laboratories & contract research organizations, Hospitals & surgical centers, Cell & tissue banks, Other End Users.
Global Stem Cell Manufacturing Market, By Region:
North America dominates the prime share of the stem cell manufacturing market; and this is due to the public-private funding and grants, extensive in progress stem cell research activities and support for the clinical evaluation of stem cells.
'
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Stem Cell Manufacturing Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Global Stem Cell Manufacturing Market, By Product, 2019-2030 (USD Million)
6.1. Consumables
6.1.1. Culture Media
6.1.2. Other Consumables
6.2. Instruments
6.2.1. Bioreactors and Incubators
6.2.2. Cell Sorters
6.2.3. Other Instruments
6.3. Stem Cell Lines
6.3.1 Embryonic stem cells (ESC)
6.3.2 Hematopoietic stem cells (HSC)
6.3.3 Induced Pluripotent Stem cells (iPSC)
6.3.4 Mesenchymal stem cells (MSC)
6.3.5 Multipotent adult progenitor stem cells
6.3.6 Neural Stem cells (NSC)
7. Global Stem Cell Manufacturing Market, By Application, 2019-2030 (USD Million)
7.1. Research Applications
7.1.1. Life science research
7.1.2. Drug discovery and development
7.2. Clinical Application
7.2.1. Allogenic stem cell therapy
7.2.2. Autologous stem cell therapy
7.3. Cell & Tissue Banking Applications
8. Global Stem Cell Manufacturing Market, By End-User, 2019-2030 (USD Million)
8.1. Academic institutes, Research laboratories & contract research organizations
8.2. Cell & tissue banks
8.3. Hospitals & surgical centres
8.4. Other End Users
8.5. Pharmaceutical & Biotechnology Companies
9. Global Stem Cell Manufacturing Market, By Region, 2019-2030 (USD Million)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia-Pacific
9.4. South America
9.4.1. Brazil
9.4.2. Argentina
9.4.3. Rest of South America
9.5. Middle East & Africa
9.5.1. Kingdom of Saudi Arabia
9.5.2. United Arab Emirates
9.5.3. Rest of Middle East & Africa
10. Company Profiles
10.1. Anterogen
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Becton
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. Bio-Rad Laboratories
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. Bio-Techne Corporation
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Cellgenix GMBH
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. Corning Inc.
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Danaher Corporation
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. Dickinson and Company
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.9. Eppendorf AG
10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments
10.10. Fujifilm Holdings Corporation
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
10.11. Getinge
10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments
10.12. Himedia Laboratories
10.12.1. Company details
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments
10.13. Lonza Group AG
10.13.1. Company details
10.13.2. Financial outlook
10.13.3. Product summary
10.13.4. Recent developments
10.14. Merck Millipore
10.14.1. Company details
10.14.2. Financial outlook
10.14.3. Product summary
10.14.4. Recent developments
10.15. Miltenyi Biotec
10.15.1. Company details
10.15.2. Financial outlook
10.15.3. Product summary
10.15.4. Recent developments
10.16. Promocell
10.16.1. Company details
10.16.2. Financial outlook
10.16.3. Product summary
10.16.4. Recent developments
10.17. Sartorius AG
10.17.1. Company details
10.17.2. Financial outlook
10.17.3. Product summary
10.17.4. Recent developments
10.18. Stemcell Technologies
10.18.1. Company details
10.18.2. Financial outlook
10.18.3. Product summary
10.18.4. Recent developments
10.19. Takara Bio Group
10.19.1. Company details
10.19.2. Financial outlook
10.19.3. Product summary
10.19.4. Recent developments
10.20. Terumo BCT Inc.
10.20.1. Company details
10.20.2. Financial outlook
10.20.3. Product summary
10.20.4. Recent developments
10.21. Thermo Fisher Scientific
10.21.1. Company details
10.21.2. Financial outlook
10.21.3. Product summary
10.21.4. Recent developments
10. Company Profiles
10.1. Anterogen
10.1.1. Company details
10.1.2. Financial outlook
10.1.3. Product summary
10.1.4. Recent developments
10.2. Becton
10.2.1. Company details
10.2.2. Financial outlook
10.2.3. Product summary
10.2.4. Recent developments
10.3. Bio-Rad Laboratories
10.3.1. Company details
10.3.2. Financial outlook
10.3.3. Product summary
10.3.4. Recent developments
10.4. Bio-Techne Corporation
10.4.1. Company details
10.4.2. Financial outlook
10.4.3. Product summary
10.4.4. Recent developments
10.5. Cellgenix GMBH
10.5.1. Company details
10.5.2. Financial outlook
10.5.3. Product summary
10.5.4. Recent developments
10.6. Corning Inc.
10.6.1. Company details
10.6.2. Financial outlook
10.6.3. Product summary
10.6.4. Recent developments
10.7. Danaher Corporation
10.7.1. Company details
10.7.2. Financial outlook
10.7.3. Product summary
10.7.4. Recent developments
10.8. Dickinson and Company
10.8.1. Company details
10.8.2. Financial outlook
10.8.3. Product summary
10.8.4. Recent developments
10.9. Eppendorf AG
10.9.1. Company details
10.9.2. Financial outlook
10.9.3. Product summary
10.9.4. Recent developments
10.10. Fujifilm Holdings Corporation
10.10.1. Company details
10.10.2. Financial outlook
10.10.3. Product summary
10.10.4. Recent developments
10.11. Getinge
10.11.1. Company details
10.11.2. Financial outlook
10.11.3. Product summary
10.11.4. Recent developments
10.12. Himedia Laboratories
10.12.1. Company details
10.12.2. Financial outlook
10.12.3. Product summary
10.12.4. Recent developments
10.13. Lonza Group AG
10.13.1. Company details
10.13.2. Financial outlook
10.13.3. Product summary
10.13.4. Recent developments
10.14. Merck Millipore
10.14.1. Company details
10.14.2. Financial outlook
10.14.3. Product summary
10.14.4. Recent developments
10.15. Miltenyi Biotec
10.15.1. Company details
10.15.2. Financial outlook
10.15.3. Product summary
10.15.4. Recent developments
10.16. Promocell
10.16.1. Company details
10.16.2. Financial outlook
10.16.3. Product summary
10.16.4. Recent developments
10.17. Sartorius AG
10.17.1. Company details
10.17.2. Financial outlook
10.17.3. Product summary
10.17.4. Recent developments
10.18. Stemcell Technologies
10.18.1. Company details
10.18.2. Financial outlook
10.18.3. Product summary
10.18.4. Recent developments
10.19. Takara Bio Group
10.19.1. Company details
10.19.2. Financial outlook
10.19.3. Product summary
10.19.4. Recent developments
10.20. Terumo BCT Inc.
10.20.1. Company details
10.20.2. Financial outlook
10.20.3. Product summary
10.20.4. Recent developments
10.21. Thermo Fisher Scientific
10.21.1. Company details
10.21.2. Financial outlook
10.21.3. Product summary
10.21.4. Recent developments
